Home › Health and Wellness › Nuchev (ASX:NUC)

Nuchev’s A$750,000 funding headroom raises pressure on FY27 execution

Health and Wellness By Victor Sage 5 min read

Nuchev lifted FY26 revenue 12% to A$25.7 million, but a wider loss, weaker margins and heavier cash use have left the wellness group dependent on shareholder-backed funding. Post-year-end drawdowns reduced its available working-capital headroom to A$750,000.

  • Revenue rose 12% to A$25.684 million
  • Statutory loss widened to A$7.388 million
  • Adjusted EBITDA loss increased to A$4.556 million
  • Operating cash outflow reached A$6.639 million
  • Only A$750,000 of working-capital facilities remained available after subsequent drawdowns

Revenue growth comes with a heavier cash burden

Nuchev Limited (ASX:NUC) grew its FY26 revenue, but the numbers underneath the top line moved in the wrong direction. Revenue rose 12% to A$25.684 million, while the statutory loss after tax widened 93.2% to A$7.388 million. Adjusted EBITDA also deteriorated, with the loss increasing to A$4.556 million from A$3.343 million a year earlier.

The result was driven by a portfolio that is becoming broader but less profitable. Gross profit increased only 3.2% to A$11.205 million, as gross margin fell to 43.6% from 47.3%. Nuchev attributed the decline to changing product and channel mix, promotional activity, product and logistics costs, and a larger contribution from distribution activities. The company’s FY26 results and margin pressure were previously reported with the same focus on revenue growth failing to translate into stronger earnings.

Oli6 carries the portfolio while Practitioner underperforms

Domestic Oli6 retail remained Nuchev’s most consistent contributor, with scan sales up 30% year on year across Chemist Warehouse, Coles and Woolworths. The brand was extended beyond infant formula into children’s snacks, Nighty Night Goat functional foods and updated Full Cream Goat Milk Powder formats, supported by the Oli6Goat.com digital platform.

“Kids’ Snacking”Caption and image © Nuchev Limited. From “Annual Report to Shareholders”, 20 Nov 2026.
“We lifted BioPractica’s brand positioning and messaging and executed a new packaging look and feel, giving the practitioner range a more premium, cohesive and ownable presence.”Caption and image © Nuchev Limited. From “Annual Report to Shareholders”, 20 Nov 2026.

The weaker link was the Practitioner business, where distributor disruption, warehouse relocation, uneven ordering and softer health-food-channel demand affected sales consistency. Nuchev launched 18 BioPractica products and a new business-to-business ecommerce platform, but the underperformance prompted a A$1.873 million non-cash impairment of goodwill associated with the bWellness cash-generating unit. The impairment reduced goodwill to nil and signals that the accounting case for the unit’s expected recovery has become more demanding.

“Rapid LOSS. control without deprivation.”Caption and image © Nuchev Limited. From “Annual Report to Shareholders”, 20 Nov 2026.

Nuchev also moved Brauer, Skin Physics and Rapid Loss from an agency arrangement to a broader distribution model in March 2026. That transition gave the group greater control over inventory, customer management and brand execution, building on the distribution model transition previously described as a way to improve margin capture and operating leverage. In practice, the expanded model also increased inventory and receivables, placing more pressure on cash before the expected revenue benefit arrives.

Going-concern uncertainty and shrinking funding headroom

Nuchev used A$6.639 million in operating cash during FY26, compared with A$3.742 million in the prior year. Inventory rose to A$7.390 million from A$5.381 million, while trade and other receivables increased to A$5.900 million from A$3.001 million. Cash at 30 June 2026 was A$2.125 million, although A$911,060 of that balance was held as security for standby letters of credit and was not available for general operating use.

The group had A$6.0 million in unsecured working-capital facilities at year end, with A$3.5 million drawn and A$2.5 million available. The facilities were provided by substantial shareholders, including H&S Group, which is also a distribution partner and related party. After year end, Nuchev drew a further A$750,000 in July and A$1.0 million in August, leaving A$5.25 million drawn and just A$750,000 available across the facilities.

The directors said the going-concern basis remained appropriate, but the financial statements disclose a material uncertainty because the forecasts depend on revenue growth, margin improvement, working-capital discipline and further facility drawdowns. Nuchev has not issued formal FY27 earnings guidance. Its stated test for the year ahead is whether domestic Oli6 momentum, Brauer’s first full year under distribution, a rebuilt Practitioner channel and selected new launches can produce better contribution and cash conversion before the funding buffer becomes the binding constraint.

A potential source of upside remains the Nouvlait matter. The Shanghai Arbitration Commission issued a final award in Nuchev’s favour, as detailed in the Shanghai arbitration award, but the company has not recognised any recovery and continues to describe the amount and timing as uncertain. Until cash is actually recovered, the balance sheet must be judged on the business it has today rather than on a legal claim it may eventually collect.

Bottom Line?

FY27 will need to show more than revenue growth: Nuchev must convert its expanded portfolio into higher margins, lower cash burn and enough liquidity to reduce reliance on shareholder funding.

Questions in the middle?

  • Can the broader Brauer distribution model generate sufficient margin and cash to offset its working-capital demands?
  • Will the Practitioner business regain consistent ordering and customer activity after the goodwill impairment?
  • How quickly can Nuchev improve operating cash flow before its remaining A$750,000 funding headroom is tested?

Sources